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esponsibility of InsAbstract The sodium/glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose
reabsorption in the kidney, and currently, SGLT2 inhibitors are considered as promising
hypoglycemic agents for the treatment of type 2 diabetes mellitus. By constructing CHO cell lines
that stably express the human SGLT2 transmembrane protein, along with a ﬂuorescent glucose
transporter assay that uses 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]2-deoxyglucose (2-
NBDG) as a glucose analog, we have developed a nonradioactive, cell-based assay for the
discovery and characterization of SGLT2 inhibitors.
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Previous research has shown that about 180 g of glucose is ﬁltered
through human kidney glomeruli every day, and more than 95%
is reabsorbed in the S1 and S2 segments of the proximal tubule.
Two sodium/glucose cotransporters (SGLT 1 and 2) are believed
to be responsible for this reuptake. Based on pharmacokinetic
studies with several species, SGLT1 is a high-afﬁnity glucose
transporter (Km 0.3–0.5 mM) with a 2:1 sodium:glucose coupling
ratio, and is mainly located in the S3 segment of renal tubule,
although there is some expression in the digestive tract. SGLT2 is
a low-afﬁnity glucose transporter (Km 5–6 mM) with a 1:1
sodium:glucose coupling ratio and a distribution along the S1
and S2 segments of the kidney tubule1–2.
As a result, these Naþ/glucose cotransporters, especially
SGLT2, are responsible for most of the glucose adaptive
reabsorption and play an important role in body glucose home-
ostasis. On the other hand, abnormal expression and dysfunction
of SGLT2 has been found in the onset and progression of
diabetes, and may contribute to the chronic hyperglycemia and
glucotoxicity leading to b-cell dysfunction3–4. By decreasing
glucose reabsorption in kidney and increasing urinary glucose
excretion, SGLT2 inhibitors can normalize the blood glucose level
and decrease glucotoxicity to organs and tissues, including
pancreatic islet cells and the microvasculature, and can be
considered as hypoglycemic agents for type 2 diabetes mellitus.
These agents may also prevent the development of diabetic
complications5–8.
Phlorizin had been identiﬁed as an inhibitor for both SGLT1
and SGLT2, and several phlorizin derivatives have been devel-
oped to speciﬁcally inhibit SGLT2. Dapagliﬂozin and Canagli-
ﬂozin were the ﬁrst-in-class oral SGLT2 inhibitors, which have
been proven to be effective when used alone or in combination
with available antidiabetic drugs in Phase III clinical trials9,10.
Although the risk–beneﬁt proﬁle has not been fully character-
ized, several clinical trials are currently underway11,12.
Screening approaches for the discovery of SGLT2 inhibi-
tors have been based on sodium-dependent glucose uptake
measurements, and generally included radiolabeled substrates
and SGLT2-expressing host cells13,14. In this study we intro-
duce a cell-based ﬂuorescence assay for sodium-dependent
glucose uptake that can be used to identify SGLT2 inhibitors.2. Materials and methods
2.1. Chemicals and reagents
Trizol Reagent, Dulbecco’s modiﬁed Eagle’s medium (DMEM)/
F12, lipofectamine 2000, and 2-NBDG were purchased from
Invitrogen (USA). Cell culture plates were from Corning-Costar
(USA). Fetal bovine serum (FBS) was a product of Biochrome
AG (Germany). A ﬁrst-strand cDNA synthesis kit was purchased
from Vigorous (Beijing, China). A SYBR green PCR kit (SYBR
Premix Ex TaqTM) was obtained from Takara (Japan). Phlorizin
was purchased from Sigma-Aldrich (USA).2.2. Cell culture and plasmid transfection
Chinese hamster ovary (CHO) cells were purchased from the
American Type Culture Collection and propagated in DMEM/F12 supplemented with 10% FBS and 1% penicillamine-
streptomycin at 37 1C in 5% CO2 and humidiﬁed air.
To establish human SGLT2 (hSGLT2) expression and
activity in cell membranes, we inserted the hSGLT2 full-
length cDNA (NCBI reference sequence: NM_003041.3) into
the plasmid vector Peak13CD5L–GFP to construct an SGLT2
expression plasmid with a ﬂuorescent expression marker
(GFP), Peak13CD5L–hSGLT2–GFP. For cell-based glucose
uptake assays the GFP cassette was removed, yielding the
Peak13CD5L–hSGLT2 expression plasmid. In transient trans-
fection experiments the cells were seeded in 6-well plates for
24 h, reaching 50–60% conﬂuence, and then the transfection
mixture containing 3 mg plasmid DNA and 4.5 mg lipofectmine
2000 was added to the cell culture medium. After incubating
for 48 h, the cells were harvested for experimental assays.
2.3. Fluorescence microscopy
The Peak13CD5L–hSGLT2–GFP plasmid was transiently trans-
fected into CHO cells, and after 48 h the cells were visualized and
photographed on the confocal laser microscope (Leica TCS SP2,
Germany) with ﬁlters for green ﬂuorescence protein.
2.4. Stable cell line construction
CHO cells transfected with the Peak13CD5L–hSGLT2 plasmid
were selected after 48 h of culture by adding 1.2–2.0 mg/mL of
puromycin to the medium. Non-transfected CHO cells cultured
in the same medium served as the negative control. After 3–5
days of culture, the negative control cells died of puromycin
toxicity and the transfected cells were harvested and diluted for
monoclone culture in 96-well plates for at least 10 days.
After propagation of the monoclone cells to stable cell lines,
total RNA was isolated using Trizol Reagent, followed by reverse
transcriptase reactions using a ﬁrst-strand cDNA synthesis kit.
The quantitative real-time polymerase chain reaction (PCR) was
used to identify hSGLT2-expressing cell lines using the SYBR
green PCR kit. The primers for hSGLT2 used in RT-PCR
were: 50–GCAGGCTCGGCACCAGAGATG–30 (forward), and
50–TGGACCACAAGCCAACGCCA–30 (reverse). To ensure
stable transfection, the RT-PCR-identiﬁed cell line was further
cultured in puromycin-containing medium and passaged for ﬁve
or more generations, and conﬁrmed by RT-PCR as needed.
2.5. Sodium-dependent glucose uptake assay
Choline buffer, prepared for cell incubations under Naþ-free
conditions, contained 140 mM choline chloride, 5 mM KCl,
2.5 mM CaCl2, 1 mM MgSO4, 1 mM KH2PO4, and 10 mM
HEPES (pH¼7.4, adjusted with 2.5 M Tris). Sodium buffer
contained 140 mM NaCl instead of choline chloride and was
used for cell incubations to measure NBDG and glucose
uptake in the presence of sodium.
For the Naþ/glucose cotransporter assay we used stably
transfected cells with the Peak13CD5L–hSGLT2 plasmid.
Cells were harvested and seeded into the poly-lysine pre-
coated 96 well plates at 40,000–60,000 cells per well. After 10-h
adherent growth, the cells were washed with 200 mL choline
buffer and serum-starved for at least 1 h. The buffer was
replaced with 50 mL of sodium buffer containing vehicle
(DMSO), SGLT2 inhibitor (Phlorizin) or a candidate SGLT2
Figure 1 Fluorescent image of hSGLT2–GFP fusion protein expression in CHO cells. The ﬂuorescence of the hSGLT2–GFP fusion
protein was obtained by a confocal laser microscope 2 days after transfection of the Peak13CD5L–hSGLT2–GFP plasmid into CHO
cells. Both the ﬂuorescent images (A and C) and the bright ﬁeld images (B and D) were taken for two selected ﬁelds. The scale bar in the
images is 37.5 mm and 18.75 mm.
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(50 mM ﬁnal concentration) or D-glucose (5 mM ﬁnal con-
centration) in 50 mL of sodium buffer. The concentration of
candidate compounds was usually set at 106 M. After being
incubated at 37 1C for 60 min, the buffer was discarded and
the cells were rinsed three times in choline buffer and released
and lysed with 50 mL cold lysis buffer (1% Nonidet P-40, 1%
sodium deoxycholate, 40 mM KCl, 20 mM Tris, pH 7.4). The
ﬂuorescent intensity of the cell lysate was detected on a
Bioteck Synergy 2 microplate reader (Excitation¼488 nm,
Emission¼520 nm). The amount of NBDG taken up by the
cells in 60 min was determined from a standard curve of
100 pM to 100 mM of NBDG in lysis buffer.
2.6. Statistical analysis
All values are presented as mean7S.E.M. The Sigma Plot
software was used for data analysis.3. Results
3.1. Optimized human SGLT2 transporter expression in CHO
cells
It has been reported previously that several host cells could be
used to express SGLT2 recombinant protein, including HEK293,xenopus oocytes, CHO and COS-7 cells. In this study, both
HEK293 and CHO cells were successfully transfected with our
plasmid constructs and expressed high levels of recombinant
hSGLT2 protein. CHO cells were selected for further character-
ization due to their better adhesion properties and greater stability
to repeated buffer changes during the glucose uptake assays.
Compared with the previous plasmids that we have used for
hSGLT2 expression, the CHO cells transfected with
Peak13CD5L–hSGLT2–GFP express a high level of hSGLT2–
GFP ﬂuorescent fusion protein in the cell membrane (Fig. 1).
3.2. Identiﬁcation of stable cell lines by RT-PCR
To identify stable hSGLT2-expressing cells, RT-Real Time
PCR analysis was carried out with puromycin-resistant CHO
monoclone cells. Relative gene expression was determined by
calculating the 2DDCT value. With comparison to expression
of hSGLT2 in non-transfected CHO cells, multiple cell lines
were identiﬁed in which the expression level of hSGLT2 was
200-fold greater than that of the negative control (Fig. 2).
3.3. Optimized incubation buffer for the ﬂuorescent glucose
uptake assay
To measure the sodium-dependent glucose uptake activity of
hSGLT2 and the inhibitory potency of candidate inhibitors,
Yi Huan et al.100several buffer recipes were tested which differed in the
concentration of NBDG, with or without supplemented
glucose. Under these conditions NBDG uptake was measured
in the presence or absence of phlorizin (Table 1). Results
indicated that the sodium buffer with 25–100 mM of NBDG,
supplemented with 5 mM of glucose was suitable for the
ﬂuorescent glucose uptake assay. Under these conditions the
IC50 for phlorizin was approximately 10
6 M (Fig. 3).3.4. Concentration-dependent inhibition of hSGLT2 by
phlorizin
To identify the practicability of this ﬂuorescent glucose uptake
assay for SGLT2 inhibitor discovery, we measured the inhibi-
tion of NBDG uptake by phlorizin in the concentration range
107 to 105 M. Results showed that NBDG uptake decreased
as the concentration of phlorizin increased (Table 2) and the
potential concentration-dependent inhibition ability is shown
in Fig. 4.Figure 2 Relative gene expression in stably transfected hSGLT2
cells. Several stable cell lines (shown as Arabic numbers) were
examined for human SGLT2 gene expression by real-time quan-
titative PCR. The results are shown as arbitrary units (A.U.) of
relative quantitation values (2DDCT), using non-transfected CHO
cells as a control calibrator and b-actin as reference gene. Each
bar represents the mean7S.E.M. of triplicate determinations.
Po0.01 vs. control.
Table 1 NBDG uptake by cells with different incubation mixtur
Concentration of NBDG (mM) Sodium buffer with glucos
Phlorizin () Ph
25 10.7672.14 2
50 39.34711.41 10
100 59.0173.82 32
200 110.6674.88 70
Values were represented as mean7S.E.M. of three experiments.
nPo0.05, NBDG uptake of phlorizin group vs. no phlorizin group4. Discussion
Recently, the SGLT family members, and most importantly
SGLT2, have been considered as important contributors to
the pathophysiology of diabetes mellitus. Several analogs of
phlorizin that act as SGLT2 inhibitors are currently in phase
II clinical trials. Current in vitro methods to screen for
effective SGLT2 inhibitors utilize radioactive substrates, with
their inherent risks. NBDG is a ﬂuorescent analog of glucose
which is used in our laboratory for the direct measurement of
glucose uptake15 and for assessing hepatic glucose production
in mice during hyperinsulinemic euglycemic clamp16. In the
current study we utilized the ﬂuorescent glucose analog
NBDG to measure sodium-dependent glucose transport by
SGLT2 and to establish an assay for the identiﬁcation of
SGLT2 inhibitors. Although nonradioactive assays have been
described by others17, we successfully applied this approach
with a recombinant hSGLT2-expressing CHO cell line.
We found that the sodium buffer with 5 mM glucose was
much more effective than the buffer without glucose, which
can be explained in part in that the concentration of glucose inFigure 3 Inhibition of NBDG uptake by phlorizin in the
optimized incubation buffer. Inhibition of NBDG uptake by
phlorizin (106 M) was measured in Sodium buffer with (black
bar) or without (white bar) 5 mM glucose. The concentrations of
NBDG in the buffer were set at 25, 50, 100 and 200 mM. Data are
shown as mean7S.E.M. in three parallel experiments. Po0.05
vs. data measured in Sodium buffer with 25 mM NBDG and
5 mM glucose. #Po0.05 vs. data measured in Sodium buffer with
25 mM NBDG in the absence of 5 mM glucose.
es.
e Sodium buffer without glucose
lorizin (þ) Phlorizin () Phlorizin (þ)
.2371.54n 18.5173.50 5.1472.03n
.0874.24 35.3770.61 19.7772.10n
.7571.17n 70.0672.45 53.0077.80
.4572.79n 149.9078.56 130.33720.26
under the same incubation conditions.
Table 2 NBDG uptake by the cells with different con-
centrations of phlorizin.
Concentration (M) NBDG uptake
Control 21.6070.50
107 17.5370.69n
106 16.1270.54n
105 5.1971.94n
Values were represented as mean7S.E.M. of three experiments.
nPo0.05, NBDG uptake with phlorizin vs. control.
Figure 4 Concentration-dependent inhibition of SGLT2 by
phlorizin. In the NBDG uptake assay the concentrations of
phlorizin ranged from 107 to 105 M. Sodium buffer with
25 mM NBDG and 5 mM glucose was used in all assays. Data
are shown as mean7S.E.M. in three parallel experiments.
A cell-based ﬂuorescent glucose transporter assay for SGLT2 inhibitor discovery 101this buffer approaches the physiological concentration in cells,
and falls in the range reported for the Km of SGLT2. In our
study, phlorizin, an established SGLT2 inhibitor, showed
good inhibitory ability and potential in the incubation buffer
under a wide range of NBDG concentrations. For large scale
screening experiments we recommend using sodium buffer
with 50 mM NBDG and 5 mM glucose supplement, based on
the stability and reliability of the results obtained herein.
Our SGLT2 expression plasmid yielded a high level of
expression and localization of SGLT2 in the plasma mem-
brane CHO cells, even in transiently transfected cells. Further-
more, the stable cell line clones can not only simplify the assay
by bypassing the transfection step, but also maintain the
consistency of results in subsequent screening assays. This
method is currently being used in our laboratory in screening
for SGLT2 inhibitors, and the stable cell line will be used for
high-throughput screening in the future.Acknowledgments
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